Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Underwater 2D acoustic sensitivity analysis of permanent magnet synchronous motors.

Science progress·2026
Same author

Ribosome stress meets disulfidptosis: HOIL-1 safeguards cell fate during nutrient deprivation.

Cell death and differentiation·2026
Same author

Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.

Nature communications·2026
Same author

Editorial: Metabolic cell death in cancer: innovative therapeutic avenues for cancer treatment.

Frontiers in oncology·2026
Same author

Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

Cell·2026
Same author

DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer.

Cancer research·2026

Related Experiment Video

Updated: Oct 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Iron out KRAS-driven cancer.

Guang Lei1,2, Boyi Gan2

  • 1Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

The Journal of Experimental Medicine
|March 9, 2022
PubMed
Summary

Targeting KRAS-driven cancers selectively is challenging. Researchers developed a drug delivery method exploiting cancer cells' iron addiction to inhibit KRAS signaling only in tumors, not normal tissues.

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

Related Experiment Videos

Last Updated: Oct 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K
Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Delivery

Background:

  • Targeting oncogenic KRAS mutations in cancers remains a significant therapeutic challenge.
  • Developing strategies that spare normal tissues from toxicity is crucial for effective cancer treatment.
  • KRAS-driven cancers exhibit a unique dependency on iron, known as iron addiction.

Purpose of the Study:

  • To design a novel drug delivery approach for selective inhibition of KRAS signaling in KRAS-mutant tumors.
  • To leverage the concept of KRAS-induced iron addiction for targeted cancer therapy.
  • To develop a strategy that minimizes off-target effects in normal tissues.

Main Methods:

  • Utilizing a drug delivery system designed to exploit the iron addiction of KRAS-mutant cancer cells.
  • Developing a method for selective inhibition of KRAS signaling pathways.
  • Evaluating the efficacy and specificity of the drug delivery approach in preclinical models.

Main Results:

  • Demonstrated successful selective inhibition of KRAS signaling specifically in KRAS-mutant tumors.
  • Showcased that the drug delivery approach spares normal tissues from adverse effects.
  • Provided evidence for the feasibility of targeting KRAS-driven cancers via iron addiction.

Conclusions:

  • The developed drug delivery strategy offers a promising new approach for treating KRAS-driven cancers.
  • Targeting KRAS-induced iron addiction represents a viable therapeutic avenue for largely incurable KRAS-mutant malignancies.
  • This strategy holds potential for improving patient outcomes by enabling targeted cancer therapy.